225 related articles for article (PubMed ID: 30841748)
1. Correlation analysis of fundus autofluorescence, spectral domain optical coherence tomography, and visual function in patients with diabetic macular oedema treated with intravitreal ziv-aflibercept.
Hernandez-Da Mota SE; Melo-Granados EAR; Fromow-Guerra J; Bejar-Cornejo F; Gallego-Pinazo R; Rodríguez-Ayala E
Eur J Ophthalmol; 2019 May; 29(3):271-277. PubMed ID: 30841748
[TBL] [Abstract][Full Text] [Related]
2. Intravitreal aflibercept for diabetic macular oedema: Moorfields' real-world 12-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Sim D; Patel PJ; Keane PA; Hykin PG; Sivaprasad S; Menon D; Bruynseels A; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2020 May; 30(3):557-562. PubMed ID: 30808179
[TBL] [Abstract][Full Text] [Related]
3. INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA: A Pilot Study.
Andrade GC; Dias JR; Maia A; Farah ME; Meyer CH; Rodrigues EB
Retina; 2016 Sep; 36(9):1640-5. PubMed ID: 26991646
[TBL] [Abstract][Full Text] [Related]
4. Ziv-aflibercept in macular disease.
Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal aflibercept for diabetic macular oedema in real-world: 36-month visual acuity and anatomical outcomes.
Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2021 May; 31(3):1201-1207. PubMed ID: 32429690
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
Spooner K; Fraser-Bell S; Hong T; Chang A
Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
[TBL] [Abstract][Full Text] [Related]
7. Three-month outcome of intravitreal ziv-aflibercept in eyes with diabetic macular oedema.
Mansour AM; Dedhia C; Chhablani J
Br J Ophthalmol; 2017 Feb; 101(2):166-169. PubMed ID: 27190127
[TBL] [Abstract][Full Text] [Related]
8. Three-month outcomes of ziv-aflibercept in the treatment of diabetic macular oedema.
Ashraf M; Souka AA; El Kayal H; El Manhaly M; Abdallah MH
Acta Ophthalmol; 2016 Nov; 94(7):e669. PubMed ID: 27227354
[No Abstract] [Full Text] [Related]
9. Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection.
Nawar AE; Wasfy T; Shafik HM
BMC Ophthalmol; 2022 Jun; 22(1):287. PubMed ID: 35768859
[TBL] [Abstract][Full Text] [Related]
10. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
[TBL] [Abstract][Full Text] [Related]
11. One-year real-life results on effect of intravitreal aflibercept in patients with diabetic macular oedema switched from ranibizumab.
Lukic M; Williams G; Shalchi Z; Patel PJ; Hykin PG; Hamilton RD; Rajendram R
Eur J Ophthalmol; 2021 May; 31(3):1171-1176. PubMed ID: 32452251
[TBL] [Abstract][Full Text] [Related]
12. Ranibizumab versus aflibercept for diabetic macular edema: 18-month results of a comparative, prospective, randomized study and multivariate analysis of visual outcome predictors.
Chatzirallis A; Theodossiadis P; Droutsas K; Koutsandrea C; Ladas I; Moschos MM
Cutan Ocul Toxicol; 2020 Dec; 39(4):317-322. PubMed ID: 32722955
[TBL] [Abstract][Full Text] [Related]
13. NATURAL HISTORY AND PREDICTORS OF VISION LOSS IN EYES WITH DIABETIC MACULAR EDEMA AND GOOD INITIAL VISUAL ACUITY.
Lent-Schochet D; Lo T; Luu KY; Tran S; Wilson MD; Moshiri A; Park SS; Yiu G
Retina; 2021 Oct; 41(10):2132-2139. PubMed ID: 33734192
[TBL] [Abstract][Full Text] [Related]
14. Fundus autofluorescence in the evaluation of diabetic macular edema treatment response.
Mota SEH; Béjar-Cornejo F; Lima-Gómez V; Rodríguez-Ayala E
Gac Med Mex; 2021; 157(4):397-403. PubMed ID: 35133337
[TBL] [Abstract][Full Text] [Related]
15. Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Alagorie AR; Nittala MG; Velaga S; Zhou B; Rusakevich AM; Wykoff CC; Sadda SR
JAMA Ophthalmol; 2020 Aug; 138(8):851-857. PubMed ID: 32584384
[TBL] [Abstract][Full Text] [Related]
16. AFLIBERCEPT FOR PERSISTENT DIABETIC MACULAR EDEMA: Forty-Eight-Week Outcomes.
Bahrami B; Hong T; Schlub TE; Chang AA
Retina; 2019 Jan; 39(1):61-68. PubMed ID: 30015767
[TBL] [Abstract][Full Text] [Related]
17. Functional and anatomic results of up to 24 months aflibercept treatment for diabetic macular edema in real-life setting.
Tsapardoni FN; Makri OE; Lagogiannis AP; Tsekouras IK; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD
Hell J Nucl Med; 2019; 22 Suppl 2():47-54. PubMed ID: 31802045
[TBL] [Abstract][Full Text] [Related]
18. Comparison of aflibercept and ranibizumab in diabetic macular edema associated with subretinal detachment.
Ozkaya A; Demir G; Kirmaci A
Eur J Ophthalmol; 2020 Mar; 30(2):363-369. PubMed ID: 30757913
[TBL] [Abstract][Full Text] [Related]
19. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
[TBL] [Abstract][Full Text] [Related]
20. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
Ho VY; Yeh S; Olsen TW; Bergstrom CS; Yan J; Cribbs BE; Hubbard GB
Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
